Keating Financial Advisory Services’s Integra LifeSciences IART Stock Holding History

Keating Financial Advisory Services’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$934	Buy	+52	New	+$727	﹤0.01%	2190

Other funds holding IART

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Keating Financial Advisory Services's IART Position: Q2 2026 in Review

Keating Financial Advisory Services opened a new position in Integra LifeSciences (IART) in Q2 2026: 52 shares worth $934. The stake represents ﹤0.01% of the portfolio and ranks #2190 among its holdings.

212 funds tracked by Wall St. Rank hold IART as of Q2 2026.

Keating Financial Advisory Services held 52 shares of Integra LifeSciences worth $934 as of Q2 2026.
Integra LifeSciences was a new Keating Financial Advisory Services position in Q2 2026.
Integra LifeSciences made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2190 holding.
212 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.